A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Inclusion Criteria:

• Subjects with histologically or cytologically-documented NSCLC
• Locally advanced, unresectable (Stage III) NSCLC
• World Health Organization (WHO) performance status 0-1
• At least one measurable lesion, not previously irradiated
• Must have a life expectancy of at least 12 weeks at randomization
• Adequate lung function: Pre- or post-bronchodilator forced expiratory volume 1 of 1.0L or >40% predicted value and DLCO >30% predicted value
• Must provide an archived tumor tissue block(or at least 15 newly cut unstainedslides)≤3 years old; if archived sample unavailable then must provide a recent(≤3months) tumor biopsy.

Exclusion Criteria:

• Mixed small-cell and NSCLC histology
• Receipt of prior or current cancer treatment, including but not limited to, radiationtherapy, investigational agents, chemotherapy, Durvalumab and mAbs.
• Prior exposure to immune-mediated therapy, including but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies.
• Patients whose radiation treatment plans are likely to encompass a volume of wholelung receiving ≥20 Gy in total (V20) of more than 35% of lung volume
• Planned radiation cardiac dose V50>25%
• Any medical contraindication of platinum-based doublet chemotherapy as listed in thelocal labelling or known allergy/hypersensitivity to investigational product and/orits excipients
• History of the following: allogeneic organ transplantation, active or prior autoimmuneor inflammatory disorders, another primary malignancy, leptomeningeal carcinomatosis,active primary immunodeficiency
• Uncontrolled intercurrent illness or active infection